Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack

A technology of medicinal salts and compounds, applied in the field of anti-hyperglycemic agents, can solve the problems not mentioned etc.

Inactive Publication Date: 2003-01-01
DAIICHI SANKYO CO LTD
View PDF26 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In the aforementioned patent documents there is no mention of the use of the compounds identified in the present application for the treatment of patients with impaired glucose tolerance in order to prevent or delay the onset of NIDDM and the complications caused by it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0177] In a previously unknown, randomized outpatient trial, the test compound (+)-5-[[4-[(3,4-dihydro-6- Hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) Effects on glucose tolerance and insulin sensitivity were compared with placebo. The trial on impaired glucose tolerance (IGT) included a 2-week screening period and a 12-week treatment period. 56 patients were randomized to treatment with placebo or troglitazone 400mg / day. Oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIGTT) were performed before drug treatment and after 6 and 12 weeks of randomized treatment to determine insulin sensitivity.

[0178] The patients involved in this study were reasonably healthy adults, and their IGT was expressed by OGTT according to the World Health Organization (WHO) standard (Harris M.I., Hadden W.C., Knowler W.C., Berrett P.H., International Criteria for the Diagnosis of Diabete...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising thereform are disclosed.

Description

technical field [0001] The present invention relates to compounds which can be used to treat impaired glucose tolerance to prevent or delay the onset of non-insulin dependent diabetes mellitus (NIDDM). More specifically, the present invention relates in one embodiment to the administration to a patient of certain known thiazolidinedione derivatives and related antihyperglycemic agents which reduce fasting insulin concentrations and restore normal glucose tolerance in humans , thereby preventing or delaying the onset of NIDDM or its complications. Background technique [0002] Diabetes is one of the most prevalent chronic diseases worldwide, with considerable personal and financial burdens on patients, their families and society. There are different types of diabetes with different etiologies and pathogens. For example, diabetes is a disorder of carbohydrate metabolism characterized by hyperglycemia and glucosuria, resulting from insufficient productio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D277/20A61K31/41A61K31/42A61K31/421A61K31/423A61K31/425A61K31/426A61K31/427A61K31/44A61K31/4439A61K31/495A61K31/505A61P3/06A61P3/08A61P3/10A61P5/50A61P9/12A61P13/02A61P15/00A61P25/02A61P43/00C07D263/44C07D263/56C07D277/34C07D291/04C07D413/14C07D417/06C07D417/10C07D417/12
CPCA61K31/42A61K31/495A61K31/4439A61K31/41A61K31/505A61K31/425A61K31/427A61K31/44A61K31/426A61P13/02A61P15/00A61P25/02A61P3/06A61P3/08A61P43/00A61P5/50A61P9/12A61P3/10
Inventor J·奥列夫斯基T·安东努齐D·罗克伍德R·诺里斯
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com